The Effect of pH on the In Vitro Antifungal Activity of SCY-078

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis

Combination Therapy with SCY-078 and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Ibrexafungerp: Activity against Pneumocystis

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.